SYNPO

Across TCGA pan-cancer cohorts, SYNPO mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SYNPO data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SYNPO mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SYNPO expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where SYNPO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.854	0.677	.001	43	view →
LUAD	DFS	Median	II,III,IV	0.661	0.994	<.001	27	view →
CCRCC	DFS	Median	All	0.848	0.977	.003	18	view →
LSCC	OS	Quartile	II,III,IV	0.674	1.000	.003	15	view →
UCEC	OS	Median	II,III,IV	0.647	1.000	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SYNPO–PDAC (DFS)

Open the PDAC breakdown →